| pubmed-article:15013300 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15013300 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15013300 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:15013300 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:15013300 | lifeskim:mentions | umls-concept:C0724693 | lld:lifeskim |
| pubmed-article:15013300 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15013300 | pubmed:dateCreated | 2004-3-11 | lld:pubmed |
| pubmed-article:15013300 | pubmed:abstractText | Erectile dysfunction (ED) is more frequent among end-stage renal failure patients than the normal population. Sildenafil citrate has been successfully used for the symptomatic treatment of erectile dysfunction. The aim of this study was to determine the efficacy and safety of sildenafil citrate in the treatment of ED in patients on hemodialysis. Fifty-five hemodialysis patients above 18 years suffering from ED with steady sexual partners were included in the study. The first five and fifteenth questions of the International Index of Erectile Function were employed to evaluate ED in the patient group. A Single 50-mg sildenafil citrate tablet was prescribed for each patient. The patients were encouraged to take it on the day after hemodialysis and 1 hour before sexual intercourse. The erectile function of the patients after the treatment was re-evaluated in the same manner by International Index of Erectile Function. The ages of the patients ranged between 30 and 73 years (mean 50.6 +/- 10.9). The overall response rate was 74.5% (38/51). Side effects were nausea (n = 2), palpitation (n = 2), flushing (n = 1), and angina (n = 1). Sildenafil citrate (50 mg) was observed to be safe and effective for treatment of hemodialysis patients with careful evaluation and proper patient selection. | lld:pubmed |
| pubmed-article:15013300 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15013300 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15013300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013300 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15013300 | pubmed:issn | 0041-1345 | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:Ozkarde?HH | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:KuoNN | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:SahinYY | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:OzdemirF NFN | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:TekinM IMI | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:AygünCC | lld:pubmed |
| pubmed-article:15013300 | pubmed:author | pubmed-author:Pe?kircio?luC... | lld:pubmed |
| pubmed-article:15013300 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15013300 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:15013300 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15013300 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15013300 | pubmed:pagination | 56-8 | lld:pubmed |
| pubmed-article:15013300 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:meshHeading | pubmed-meshheading:15013300... | lld:pubmed |
| pubmed-article:15013300 | pubmed:articleTitle | Efficacy and safety of sildenafil citrate in hemodialysis patients. | lld:pubmed |
| pubmed-article:15013300 | pubmed:affiliation | Ba?kent University, Faculty of Medicine, Department of Urology, Ankara, Turkey. | lld:pubmed |
| pubmed-article:15013300 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15013300 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
